N²-methylpterin | 13005-84-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 蝶啶及其衍生物
• 英文名称: N²-methylpterin
• 英文别名: 2-(methylamino)-4(3H)-pteridinone；2-(methylamino)-3H-pteridin-4-one
• CAS: 13005-84-0
• 化学式: C₇H₇N₅O
• 分子量: 177.165
• InChiKey: VTXDEEZAJOFOKY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  79.3
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N²-methylpterin 在 platinum(IV) oxide 氢气 、 三氟乙酸 作用下， 反应 12.0h， 生成 2-Methylamino-5,6,7,8-tetrahydro-3H-pteridin-4-one
  参考文献：
  名称：

  Structural Requirements for Inhibition of the Neuronal Nitric Oxide Synthase (NOS-I):  3D-QSAR Analysis of 4-Oxo- and 4-Amino-Pteridine-Based Inhibitors

  摘要：

  The family of homodimeric nitric oxide synthases (NOS I-III) catalyzes the generation of the cellular messenger nitric oxide (NO) by oxidation of the substrate L-arginine. The rational design of specific NOS inhibitors is of therapeutic interest in regulating pathological NO levels associated with sepsis, inflammatory, and neurodegenerative diseases. The cofactor (6R)-5,6,7,8-tetrahydrobiopterin (H(4)Bip) maximally activates all NOSs and stabilizes enzyme quaternary structure by promoting and stabilizing dimerization. Here, we describe the synthesis and three-dimensional (3D) quantitative structure-activity relationship (QSAR) analysis of 65 novel 4-amino- and 4-oxo-pteridines (antipterins) as inhibitors targeting the H(4)Bip binding site of the neuronal NOS isoform (NOS-I). The experimental binding modes for two inhibitors complexed with the related endothelial NO synthase (NOS-III) reveal requirements of biological affinity and form the basis for ligand alignment. Different alignment rules were derived by building other compounds accordingly using manual superposition or a genetic algorithm for flexible superposition. Those alignments led to 3D-QSAR models (comparative molecular field analysis (CoMFA) and comparative molecular similarity index analysis (CoMSIA)), which were validated using leave-one-out cross-validation, multiple analyses with two and five randomly chosen cross-validation groups, perturbation of biological activities by randomization or progressive scrambling, and external prediction. An iterative realignment procedure based on rigid field fit was used to improve the consistency of the resulting partial least squares models. This led to consistent and highly predictive 3D-QSAR models with good correlation coefficients for both CoMFA and CoMSIA, which correspond to experimentally determined NOS-II and -III H(4)Bip binding site topologies as well as to the NOS-I homology model binding site in terms of steric, electrostatic, and hydrophobic complementarity. These models provide clear guidelines and accurate activity predictions for novel NOS-I inhibitors.

  DOI：

  10.1021/jm020074g
• 作为产物：
  描述：

  7-Methoxy-2-methylamino-3H-pteridin-4-one 在 aluminum-mercury amalgam 、 氨 作用下， 以 甲醇 、 水 为溶剂， 反应 10.0h， 以38%的产率得到8-Methyl-2-methylamino-1,9-dihydro-purin-6-one
  参考文献：
  名称：

  Ring Transformation of Pterins to Guanines

  摘要：

  DOI：

  10.3987/r-1987-08-2091

文献信息

• Pteridines, Part CXIII
  作者：Qizheng Yao、Wolfgang Pfleiderer

  DOI：10.1002/hlca.200390025

  日期：2003.1

  compounds can be alkylated under Mitsunobu conditions to form from N2-acylpterins (see 2 and 3) and their derivatives (see 5, 6, 8, 9, 11, 13, 15, and 17) selectively the O4-alkyl derivatives 22–31, whereas the electron-donating [(dimethylamino)methyleneamino function in 46–51 gives, in a selective reaction, the N(3)-substitution (52–61). N2,N2-Dimethylpterins and 18 and 19 and N2-methylpterins 20 and 21

  蝶呤的低溶解度可通过N 2-酰化或形成N 2 -[（（二甲基氨基）亚甲基]衍生物而大大改善。这两种类型的化合物可以下被烷基化的Mitsunobu条件从到形式Ñ 2 -acylpterins（参照2和3）和它们的衍生物（参见图5，6，8，9，11，13，15，和17）选择性地将Ò 4 -烷基衍生物22 – 31，而给电子体[[（二甲基氨基）亚甲基氨基]在46 – 51在选择性反应中给出N（3）取代（52 – 61）。Ñ 2，Ñ 2个-Dimethylpterins和18个19和Ñ 2 -methylpterins 20和21直接烷基化还向Ò 4位上（32 - 35，38和39）。脱酰可以在非常温和的条件下通过溶剂解用MeOH（实现22 40，26 41），和所述的位移Ò 4- [2-（4-硝基苯基）乙基]基团在室温下，以相应的蝶啶-2,4-二胺氨前进42 - 45。N 2 -[（（二甲基氨基）亚甲基]基团的裂解可很好地与氨（62
• METHOD AND APPARATUS FOR CANCER SCREENING
  申请人：Ma Yinfa

  公开号：US20110147217A1

  公开（公告）日：2011-06-23

  A method and apparatus for detection of pteridine levels in a biological sample using CE-LIF which is useful for early cancer screening involving fully oxidizing pteridine compounds in a sample such as a urine sample, subjecting to CE-LIF to assess compound concentration, and compare to expected levels in for healthy or cancer-bearing patients.
• US9207205B2
  申请人：——

  公开号：US9207205B2

  公开（公告）日：2015-12-08